PortalPublikationenSofosbuvir, velpatasvir, and voxilaprevir for patients with ...

Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)

Standard

Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). / Vermehren, Johannes; Serfert, Yvonne; Cornberg, Markus; Stoehr, Albrecht; Klinker, Hartwig; Simon, Karl-Georg; Teuber, Gerlinde; Deterding, Katja; Schulze Zur Wiesch, Julian; Jung, Maria-Christina; Manns, Michael P; Zeuzem, Stefan; Wedemeyer, Heiner; Sarrazin, Christoph.

in: Z GASTROENTEROL, Jahrgang 58, Nr. 9, 09.2020, S. 841-846.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Vermehren, J, Serfert, Y, Cornberg, M, Stoehr, A, Klinker, H, Simon, K-G, Teuber, G, Deterding, K, Schulze Zur Wiesch, J, Jung, M-C, Manns, MP, Zeuzem, S, Wedemeyer, H & Sarrazin, C 2020, 'Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)', Z GASTROENTEROL, Jg. 58, Nr. 9, S. 841-846. https://doi.org/10.1055/a-1217-7669

APA

Vermehren, J., Serfert, Y., Cornberg, M., Stoehr, A., Klinker, H., Simon, K-G., Teuber, G., Deterding, K., Schulze Zur Wiesch, J., Jung, M-C., Manns, M. P., Zeuzem, S., Wedemeyer, H., & Sarrazin, C. (2020). Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). Z GASTROENTEROL, 58(9), 841-846. https://doi.org/10.1055/a-1217-7669

Vancouver

Vermehren J, Serfert Y, Cornberg M, Stoehr A, Klinker H, Simon K-G et al. Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). Z GASTROENTEROL. 2020 Sep;58(9):841-846. https://doi.org/10.1055/a-1217-7669

Bibtex

@article{d9a89cb9e8a545a3a289853cae65389e,
title = "Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)",
abstract = "Despite the high effectiveness of direct-acting antivirals for the treatment of hepatitis C, a small proportion of patients do not respond to approved regimens. The combination regimen of SOF/VEL/VOX was recently approved for patients with failure to prior NS5A-based treatment. In this German real-world cohort including patients with cirrhosis (27.3 %) and previous decompensation events, 12 weeks of SOF/VEL/VOX resulted in high virologic response rates irrespective of disease severity and prior DAA regimen. Adverse events were mostly mild or moderate and comparable to those seen in the approval studies.",
keywords = "Antiviral Agents/therapeutic use, Carbamates/therapeutic use, Drug Therapy, Combination, Genotype, Hepacivirus/drug effects, Hepatitis C, Chronic/drug therapy, Heterocyclic Compounds, 4 or More Rings/therapeutic use, Humans, Macrocyclic Compounds/therapeutic use, Registries, Sofosbuvir/therapeutic use, Sulfonamides/therapeutic use, Sustained Virologic Response, Treatment Outcome",
author = "Johannes Vermehren and Yvonne Serfert and Markus Cornberg and Albrecht Stoehr and Hartwig Klinker and Karl-Georg Simon and Gerlinde Teuber and Katja Deterding and {Schulze Zur Wiesch}, Julian and Maria-Christina Jung and Manns, {Michael P} and Stefan Zeuzem and Heiner Wedemeyer and Christoph Sarrazin",
note = "{\textcopyright} Georg Thieme Verlag KG Stuttgart · New York.",
year = "2020",
month = sep,
doi = "10.1055/a-1217-7669",
language = "English",
volume = "58",
pages = "841--846",
journal = "Z GASTROENTEROL",
issn = "0044-2771",
publisher = "Karl Demeter Verlag GmbH",
number = "9",

}

RIS

TY - JOUR

T1 - Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)

AU - Vermehren, Johannes

AU - Serfert, Yvonne

AU - Cornberg, Markus

AU - Stoehr, Albrecht

AU - Klinker, Hartwig

AU - Simon, Karl-Georg

AU - Teuber, Gerlinde

AU - Deterding, Katja

AU - Schulze Zur Wiesch, Julian

AU - Jung, Maria-Christina

AU - Manns, Michael P

AU - Zeuzem, Stefan

AU - Wedemeyer, Heiner

AU - Sarrazin, Christoph

N1 - © Georg Thieme Verlag KG Stuttgart · New York.

PY - 2020/9

Y1 - 2020/9

N2 - Despite the high effectiveness of direct-acting antivirals for the treatment of hepatitis C, a small proportion of patients do not respond to approved regimens. The combination regimen of SOF/VEL/VOX was recently approved for patients with failure to prior NS5A-based treatment. In this German real-world cohort including patients with cirrhosis (27.3 %) and previous decompensation events, 12 weeks of SOF/VEL/VOX resulted in high virologic response rates irrespective of disease severity and prior DAA regimen. Adverse events were mostly mild or moderate and comparable to those seen in the approval studies.

AB - Despite the high effectiveness of direct-acting antivirals for the treatment of hepatitis C, a small proportion of patients do not respond to approved regimens. The combination regimen of SOF/VEL/VOX was recently approved for patients with failure to prior NS5A-based treatment. In this German real-world cohort including patients with cirrhosis (27.3 %) and previous decompensation events, 12 weeks of SOF/VEL/VOX resulted in high virologic response rates irrespective of disease severity and prior DAA regimen. Adverse events were mostly mild or moderate and comparable to those seen in the approval studies.

KW - Antiviral Agents/therapeutic use

KW - Carbamates/therapeutic use

KW - Drug Therapy, Combination

KW - Genotype

KW - Hepacivirus/drug effects

KW - Hepatitis C, Chronic/drug therapy

KW - Heterocyclic Compounds, 4 or More Rings/therapeutic use

KW - Humans

KW - Macrocyclic Compounds/therapeutic use

KW - Registries

KW - Sofosbuvir/therapeutic use

KW - Sulfonamides/therapeutic use

KW - Sustained Virologic Response

KW - Treatment Outcome

U2 - 10.1055/a-1217-7669

DO - 10.1055/a-1217-7669

M3 - SCORING: Journal article

C2 - 32947629

VL - 58

SP - 841

EP - 846

JO - Z GASTROENTEROL

JF - Z GASTROENTEROL

SN - 0044-2771

IS - 9

ER -